Dean Capital Investments Management LLC Sells 218 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Dean Capital Investments Management LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,022 shares of the medical research company’s stock after selling 218 shares during the quarter. Dean Capital Investments Management LLC’s holdings in Thermo Fisher Scientific were worth $589,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of TMO. Nuveen Asset Management LLC raised its stake in Thermo Fisher Scientific by 10,824.0% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,928,966 shares of the medical research company’s stock valued at $566,498,000 after purchasing an additional 1,911,308 shares during the period. Jennison Associates LLC increased its stake in Thermo Fisher Scientific by 2,589.9% in the 2nd quarter. Jennison Associates LLC now owns 819,138 shares of the medical research company’s stock worth $240,564,000 after acquiring an additional 788,686 shares during the last quarter. Putnam Investments LLC increased its stake in Thermo Fisher Scientific by 2,645.9% in the 2nd quarter. Putnam Investments LLC now owns 720,795 shares of the medical research company’s stock worth $211,683,000 after acquiring an additional 694,545 shares during the last quarter. AQR Capital Management LLC increased its stake in Thermo Fisher Scientific by 38.8% in the 2nd quarter. AQR Capital Management LLC now owns 2,141,471 shares of the medical research company’s stock worth $621,561,000 after acquiring an additional 598,230 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in Thermo Fisher Scientific by 22.9% in the 2nd quarter. Janus Henderson Group PLC now owns 2,986,916 shares of the medical research company’s stock worth $877,186,000 after acquiring an additional 555,802 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors.

In related news, CEO Marc N. Casper sold 2,271 shares of the business’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $298.00, for a total transaction of $676,758.00. Following the completion of the transaction, the chief executive officer now owns 283,502 shares in the company, valued at approximately $84,483,596. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jim P. Manzi sold 1,833 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $272.93, for a total value of $500,280.69. Following the transaction, the director now owns 28,592 shares of the company’s stock, valued at approximately $7,803,614.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,833 shares of company stock worth $15,299,095. Corporate insiders own 0.45% of the company’s stock.

Shares of NYSE TMO traded up $3.71 during trading hours on Tuesday, hitting $297.24. 4,210 shares of the company traded hands, compared to its average volume of 1,265,393. The stock has a market capitalization of $118.15 billion, a price-to-earnings ratio of 26.80, a price-to-earnings-growth ratio of 1.91 and a beta of 1.14. The company has a current ratio of 1.80, a quick ratio of 1.23 and a debt-to-equity ratio of 0.56. The company’s 50 day moving average price is $290.07 and its 200 day moving average price is $283.92. Thermo Fisher Scientific Inc. has a 12 month low of $208.34 and a 12 month high of $306.00.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.88 by $0.06. The firm had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.19 billion. Thermo Fisher Scientific had a return on equity of 17.16% and a net margin of 14.24%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.62 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Tuesday, December 17th will be given a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 0.26%. The ex-dividend date is Monday, December 16th. Thermo Fisher Scientific’s dividend payout ratio is currently 6.83%.

A number of research firms have issued reports on TMO. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $305.00 to $319.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. JPMorgan Chase & Co. lifted their price objective on Thermo Fisher Scientific from $315.00 to $330.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. ValuEngine downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Needham & Company LLC lifted their price objective on Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, Credit Suisse Group reaffirmed a “buy” rating and issued a $310.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $314.45.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: Leveraged Buyout (LBO)

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.